Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
48.00    3.50 (7.87%)
Bid:
47.50
Ask:
48.50
Spread: 1.00 (2.105%)
Market Cap: £92.09m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Q3 2025 Update

16 Oct 2025 07:00

RNS Number : 5617D
Iofina PLC
16 October 2025
 

 

 

16 October 2025

 

Iofina plc

("Iofina", the "Company" or the "Group")

(AIM: IOF)

 

Q3 2025 Corporate Update

Record Quarter in Iodine Production History

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update regarding its activities during Q3 2025 (the "Period").

 

In the Period, Iofina Resources produced 215.8 metric tonnes ('MT') of crystalline iodide from its eight IOsorb® plants in Central and Northwest Oklahoma (Q3 2024: 163.9 MT). This represents a 32% increase in production, with 75 MT produced in September 2025 after IO#11 came online in July 2025. With water volumes to our plants expected to remain consistent through Q4 2025, production for H2 2025 is on track to be within the production range of 400-440 MT.

 

Pricing and demand for raw iodine have remained strong. The average realised iodine spot price is steadily above $70/kg, trending towards the mid-seventies, and prices are expected to remain at these levels for the rest of the year. The Company continues to experience strong demand for its crystalline iodine, with global iodine consumption expected to approach 40,000 MT in 2025.

 

The negotiations with our IO#12 partner have entered the final stages, and we are hopeful of signing an agreement shortly, and expect to commence the plant's foundation work by the end of the year.

 

 

President and CEO, Dr. Tom Becker, commented:

"The Company continues to execute its growth strategy as illustrated by the record month of September and Q3 2025 production increasing by 32% year on year. Importantly, production has been steady across all our plants, putting us on track for a crystalline iodine production range of 400-440 MT for the second half of the year, and ultimately, further full-year growth.

 

"With production at IO#11 commencing in July, the Company has met its target of building one new plant each year over the past three years. With negotiations for IO#12 now in the later stages, we expect to continue the delivery of a new plant for the fourth year running.

 

"With iodine prices remaining high and demand for Iofina's products only getting stronger, the Board is excited by the current outlook for the rest of the year and into 2026."

 

Enquiries:

 

Iofina plc

Dr. Tom Becker

CEO & President

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Canaccord Genuity Limited

Henry Fitzgerald-O'Connor/Harry Rees

Tel: +44 (0)20 7523 8000

 

Financial PR and Media Contact:

Yellow Jersey PR Limited

Charles Goodwin/Shivantha Thambirajah

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

 

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina operates eight IOsorb® plants in Oklahoma and consistently uses technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high-quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical celebrated its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFSRIRLELIE
Date   Source Headline
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.